News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
723,065 Results
Type
Article (41030)
Company Profile (274)
Press Release (681750)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (204880)
Career Advice (2029)
Deals (35564)
Drug Delivery (111)
Drug Development (81479)
Employer Resources (173)
FDA (16429)
Job Trends (14963)
News (346744)
Policy (32755)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2572)
Accelerated approval (35)
Adcomms (25)
Allergies (146)
Alliances (49646)
ALS (172)
Alzheimer's disease (1677)
Antibody-drug conjugate (ADC) (320)
Approvals (16697)
Artificial intelligence (523)
Autoimmune disease (160)
Automation (43)
Bankruptcy (361)
Best Places to Work (11645)
BIOSECURE Act (20)
Biosimilars (193)
Biotechnology (181)
Bladder cancer (160)
Brain cancer (58)
Breast cancer (646)
Cancer (4880)
Cardiovascular disease (407)
Career advice (1712)
Career pathing (36)
CAR-T (287)
CDC (46)
Celiac Disease (2)
Cell therapy (756)
Cervical cancer (37)
Clinical research (69705)
Collaboration (1728)
Company closure (4)
Compensation (1179)
Complete response letters (57)
COVID-19 (2720)
CRISPR (93)
C-suite (865)
Cystic fibrosis (143)
Data (6325)
Decentralized trials (2)
Denatured (25)
Depression (135)
Diabetes (504)
Diagnostics (6715)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (256)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (234)
Earnings (90296)
Editorial (58)
Employer branding (21)
Employer resources (152)
Events (117633)
Executive appointments (983)
FDA (19591)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1485)
Gene editing (200)
Generative AI (44)
Gene therapy (603)
GLP-1 (968)
Government (4668)
Grass and pollen (6)
Guidances (384)
Healthcare (18897)
HIV (62)
Huntington's disease (45)
IgA nephropathy (84)
Immunology and inflammation (256)
Immuno-oncology (61)
Indications (121)
Infectious disease (2998)
Inflammatory bowel disease (197)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (255)
Interviews (317)
IPO (16654)
IRA (50)
Job creations (3652)
Job search strategy (1430)
JPM (57)
Kidney cancer (16)
Labor market (86)
Layoffs (548)
Leadership (32)
Legal (7953)
Liver cancer (92)
Longevity (15)
Lung cancer (660)
Lymphoma (384)
Machine learning (42)
Management (59)
Manufacturing (808)
MASH (165)
Medical device (13781)
Medtech (13839)
Mergers & acquisitions (19986)
Metabolic disorders (1277)
Multiple sclerosis (164)
NASH (16)
Neurodegenerative disease (324)
Neuropsychiatric disorders (89)
Neuroscience (2930)
Neurotech (1)
NextGen: Class of 2026 (6530)
Non-profit (4516)
Now hiring (68)
Obesity (599)
Opinion (263)
Ovarian cancer (168)
Pain (202)
Pancreatic cancer (232)
Parkinson's disease (285)
Partnered (33)
Patents (509)
Patient recruitment (499)
Peanut (58)
People (59006)
Pharmaceutical (62)
Pharmacy benefit managers (30)
Phase 1 (21744)
Phase 2 (30680)
Phase 3 (22845)
Pipeline (5502)
Policy (290)
Postmarket research (2565)
Preclinical (9216)
Press Release (64)
Prostate cancer (240)
Psychedelics (48)
Radiopharmaceuticals (283)
Rare diseases (856)
Real estate (5968)
Recruiting (70)
Regulatory (24595)
Reports (53)
Research institute (2392)
Resumes & cover letters (353)
Rett syndrome (27)
RNA editing (16)
RSV (81)
Schizophrenia (150)
Series A (241)
Series B (192)
Service/supplier (11)
Sickle cell disease (98)
Special edition (22)
Spinal muscular atrophy (157)
Sponsored (42)
Startups (3622)
State (2)
Stomach cancer (18)
Supply chain (105)
Tariffs (84)
The Weekly (54)
Vaccines (1013)
Venture capital (89)
Weight loss (383)
Women's health (96)
Worklife (18)
Date
Today (152)
Last 7 days (676)
Last 30 days (2359)
Last 365 days (29916)
2026 (4139)
2025 (30217)
2024 (35249)
2023 (40103)
2022 (51231)
2021 (55762)
2020 (54123)
2019 (46565)
2018 (35041)
2017 (32143)
2016 (31522)
2015 (37590)
2014 (31361)
2013 (26382)
2012 (28585)
2011 (29284)
2010 (27353)
Location
Africa (736)
Alabama (85)
Alaska (7)
Arizona (312)
Arkansas (13)
Asia (39328)
Australia (6439)
California (11445)
Canada (3325)
China (1111)
Colorado (483)
Connecticut (484)
Delaware (342)
Europe (84768)
Florida (1719)
Georgia (362)
Hawaii (3)
Idaho (61)
Illinois (872)
India (70)
Indiana (529)
Iowa (22)
Japan (437)
Kansas (127)
Kentucky (40)
Louisiana (26)
Maine (72)
Maryland (1405)
Massachusetts (8188)
Michigan (328)
Minnesota (633)
Mississippi (5)
Missouri (129)
Montana (32)
Nebraska (28)
Nevada (124)
New Hampshire (79)
New Jersey (3038)
New Mexico (28)
New York (3008)
North Carolina (1473)
North Dakota (8)
Northern California (5601)
Ohio (338)
Oklahoma (21)
Oregon (41)
Pennsylvania (2327)
Puerto Rico (24)
Rhode Island (48)
South America (1108)
South Carolina (68)
South Dakota (1)
Southern California (4458)
Tennessee (177)
Texas (1759)
United States (40566)
Utah (340)
Vermont (1)
Virginia (265)
Washington D.C. (81)
Washington State (930)
West Virginia (4)
Wisconsin (111)
Wyoming (2)
723,065 Results for "protalix biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
February 1, 2026
·
13 min read
Press Releases
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
February 1, 2026
·
9 min read
Press Releases
Protalix BioTherapeutics to Present at Investor Summit Virtual
September 12, 2025
·
2 min read
Press Releases
Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU
October 20, 2025
·
11 min read
Press Releases
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
November 3, 2025
·
9 min read
Protalix BioTherapeutics to Present at the 2024 BIO International Convention
Protalix BioTherapeutics, Inc. announced that Dror Bashan, its President and Chief Executive Officer, will present at the upcoming 2024 BIO International Convention June 3 - 6, 2024, in San Diego, California.
May 29, 2024
·
3 min read
Press Releases
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
January 27, 2026
·
5 min read
Business
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
Protalix BioTherapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023, and provided a business update.
March 14, 2024
·
18 min read
Business
Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results
Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, reported financial results for the quarter ended March 31, 2024, and provided a business and clinical update.
May 10, 2024
·
15 min read
Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference
Protalix BioTherapeutics, Inc. (NYSE American: PLX) today announced that it will attend and present at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 at the New York Marriott Marquis in New York City.
February 23, 2024
·
2 min read
1 of 72,307
Next
